Ali Tehrani, PhD, serves as a Venture Partner for Amplitude Ventures, a capital catalyst for highly innovative companies at the point of value acceleration. Prior to joining Amplitude, Dr. Tehrani was a co-founder served as President, Chief Executive Officer, and Director of Zymeworks Inc. He led the company through numerous value creation stages, including signing nine licensing and collaboration deals with Merck, J&J, GSK, BMS/Celgene and Eli Lilly and a New York Stock Exchange public listing in April 2017. Dr. Tehrani holds both Bachelors and Masters of Science degrees in Biochemistry from the University of Massachusetts and has a Doctoral degree in Microbiology and Immunology from the University of British Columbia. Currently, he is a member of the Board of Directors of LifeSciences British Columbia, Creatus Biosciences Inc, and CQDM. Dr. Tehrani also serves as a member of the British Columbia Premier Technology Council.